Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease
Selection of oral antidiabetic drugs (OAD) in patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD) is very important because most OAD is secreted through the kidneys so dose adjustment is required. In Indonesia, short acting sulfonylureas (SU) are commonly used for the man...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Indonesian |
Published: |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
2018-09-01
|
Series: | Jurnal Penyakit Dalam Indonesia |
Subjects: | |
Online Access: | http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/202/164 |
id |
doaj-c9436896c59940eab9afb1df436c7f3a |
---|---|
record_format |
Article |
spelling |
doaj-c9436896c59940eab9afb1df436c7f3a2020-11-25T02:26:30ZindDepartment of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo HospitalJurnal Penyakit Dalam Indonesia2406-89692549-06212018-09-0153150155http://dx.doi.org/10.7454/jpdi.v5i3.202Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney DiseaseRetta C Sihotang0Rizka Ramadhani1Dicky L Tahapary2Fakultas Kedokteran Universitas Indonesia Departemen Ilmu Penyakit Dalam, RSUPN Dr. Cipto Mangunkusumo, Fakultas Kedokteran Universitas Indonesia Divisi Metabolik Endokrin, Departemen Ilmu Penyakit Dalam, RSUPN Dr. Cipto Mangunkusumo, Fakultas Kedokteran Universitas Indonesia Selection of oral antidiabetic drugs (OAD) in patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD) is very important because most OAD is secreted through the kidneys so dose adjustment is required. In Indonesia, short acting sulfonylureas (SU) are commonly used for the management of T2DM with CKD. This review article aimed to compare the effectiveness and safety of certain SU types with other OAD in T2DM with CKD. Sulfonylureas, tiazolidindion (TZD), DPP-IV-inhibitor, and SGLT-2-inhibitor were evaluated. Short acting sulfonylureas (glycazides and glipizids) and SGLT-2-inhibitor (empaglifozin and canaglifozin) may inhibit the progression of CKD in T2DM. On the contrary, pioglitazone and sitagliptin are associated with higher progression of CKD, while linagliptin has a neutral effect on deterioration of CKD. However, sitagliptin and linagliptin have lower risk of causing hypoglycemia than short acting SU. In conclusion, short acting SU can still be the primary choice for the blood glucose management in T2DM with CKD in Indonesia.http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/202/164Chronic kidney diseaseEfficacyOral antidiabeticSafetySulfonylurea |
collection |
DOAJ |
language |
Indonesian |
format |
Article |
sources |
DOAJ |
author |
Retta C Sihotang Rizka Ramadhani Dicky L Tahapary |
spellingShingle |
Retta C Sihotang Rizka Ramadhani Dicky L Tahapary Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease Jurnal Penyakit Dalam Indonesia Chronic kidney disease Efficacy Oral antidiabetic Safety Sulfonylurea |
author_facet |
Retta C Sihotang Rizka Ramadhani Dicky L Tahapary |
author_sort |
Retta C Sihotang |
title |
Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease |
title_short |
Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease |
title_full |
Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease |
title_fullStr |
Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease |
title_full_unstemmed |
Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease |
title_sort |
efficacy and safety of oral antidiabetic drugs in type 2 diabetes mellitus with chronic kidney disease |
publisher |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital |
series |
Jurnal Penyakit Dalam Indonesia |
issn |
2406-8969 2549-0621 |
publishDate |
2018-09-01 |
description |
Selection of oral antidiabetic drugs (OAD) in patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD) is very important because most OAD is secreted through the kidneys so dose adjustment is required. In Indonesia, short acting sulfonylureas (SU) are commonly used for the management of T2DM with CKD. This review article aimed to compare the effectiveness and safety of certain SU types with other OAD in T2DM with CKD. Sulfonylureas, tiazolidindion (TZD), DPP-IV-inhibitor, and SGLT-2-inhibitor were evaluated. Short acting sulfonylureas (glycazides and glipizids) and SGLT-2-inhibitor (empaglifozin and canaglifozin) may inhibit the progression of CKD in T2DM. On the contrary, pioglitazone and sitagliptin are associated with higher progression of CKD, while linagliptin has a neutral effect on deterioration of CKD. However, sitagliptin and linagliptin have lower risk of causing hypoglycemia than short acting SU. In conclusion, short acting SU can still be the primary choice for the blood glucose management in T2DM with CKD in Indonesia. |
topic |
Chronic kidney disease Efficacy Oral antidiabetic Safety Sulfonylurea |
url |
http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/202/164 |
work_keys_str_mv |
AT rettacsihotang efficacyandsafetyoforalantidiabeticdrugsintype2diabetesmellituswithchronickidneydisease AT rizkaramadhani efficacyandsafetyoforalantidiabeticdrugsintype2diabetesmellituswithchronickidneydisease AT dickyltahapary efficacyandsafetyoforalantidiabeticdrugsintype2diabetesmellituswithchronickidneydisease |
_version_ |
1724846547716276224 |